Severe hepatic injury associated with lipid formulations of amphotericin B.
A 14-year-old girl with leukemia had Doppler ultrasound evidence of hepatic necrosis, thought to be caused by a lipid formulation of amphotericin B, which has not been previously reported. It seems prudent to exert caution when retreating patients with previous hepatocellular damage with lipid formulations of amphotericin B.
Ellis
M
M
Department of Medicine, United Arab Emirates University, Al-Ain, United Arab Emirates. michael.ellis@uaeu.ac.ae
Shamoon
A
A
Gorka
W
W
Zwaan
F
F
al-Ramadi
B
B
D000293:Adolescent; D000666:Amphotericin B / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D003561:Cytarabine / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000150:complications / Q000188:drug therapy; D008081:Liposomes; D008099:Liver / Q000473:pathology*; D008107:Liver Diseases / Q000473:pathology
D008081:Liposomes; C068538:liposomal amphotericin B; D003561:Cytarabine; D005047:Etoposide; D000666:Amphotericin B; D015255:Idarubicin